New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
07:08 EDTTXMDTherapeuticsMD receives enrollment approval for Phase 3 trial of TX 12-001HR
TherapeuticsMD announced that it received approval to begin screening and enrolling subjects at its fiftieth site, the University of Florida College of Medicine, in the Company’s REPLENISH Trial, a phase 3, double-blind, placebo-controlled clinical trial designed to measure the safety and effectiveness of TX 12-001HR, the Company’s bio-identical combination 17ß-estradiol and progesterone drug candidate, in treating the symptoms of menopause.
News For TXMD From The Last 14 Days
Check below for free stories on TXMD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for TXMD

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use